|
Palo Alto, CA, June 12, 2003 — Telik, Inc. (Nasdaq:
TELK) announced that Michael M. Wick, M.D., Ph.D., chairman and
chief executive officer, will present a company update at the Thomas
Weisel Partners Growth Forum in Santa Barbara, California on Wednesday,
June 18, 2003 at 11:05 a.m. Pacific time.
A webcast of Dr. Wick’s presentation will be available live
on the Telik website, www.telik.com. A replay of the webcast will
be available on the Telik website from approximately 1:00 p.m. Pacific
time on June 18 through June 25, 2003.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TELCYTA™ (TLK286), in a Phase 3 registration trial in advanced
ovarian cancer and in earlier stage clinical trials in ovarian,
non-small cell lung and breast cancer. TLK199 is in a Phase 1-2a
trial in myelodysplastic syndrome, a form of pre-leukemia. Telik’s
product candidates were discovered using its proprietary drug discovery
technology, TRAP, which enables the rapid and efficient discovery
of small molecule drug candidates. Additional information is available
at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
